MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
1.635
-0.135
-7.63%
Closed 19:26 04/15 EDT
OPEN
1.800
PREV CLOSE
1.770
HIGH
1.850
LOW
1.620
VOLUME
94.68K
TURNOVER
0
52 WEEK HIGH
8.82
52 WEEK LOW
1.170
MARKET CAP
25.76M
P/E (TTM)
-1.4212
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ACXP last week (0408-0412)?
Weekly Report · 1d ago
Weekly Report: what happened at ACXP last week (0401-0405)?
Weekly Report · 04/08 09:42
Weekly Report: what happened at ACXP last week (0325-0329)?
Weekly Report · 04/01 09:42
Weekly Report: what happened at ACXP last week (0318-0322)?
Weekly Report · 03/25 09:43
12 Health Care Stocks Moving In Tuesday's Intraday Session
Ontrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. Fusion Pharmaceuticals stock moved upwards by 97%. SCWorx stock rose 70.74% and Enliven Therapeutics stock increased by 29.19%. Acutus Medical stock declined by 26.5% during the session.
Benzinga · 03/19 17:31
Acurx files common stock offering, no amount given
Shares in the company down 11.3% in early trade. Acurx Pharmaceuticals filed a prospectus related to the sale of shares of its common stock for an undisclosed amount. The company's stock is down 10.7% to $3.50 in early trading.
Seeking Alpha · 03/19 14:23
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers
Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.02% to 1689.96. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is +0.01% to 1378.25.
Seeking Alpha · 03/19 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Ontrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. Fusion Pharmaceuticals and Enveric Biosciences moved upwards by 97.46% and 39.09% respectively. Losers include Seelos Therapeutics and Acurx Pharmaceuticals.
Benzinga · 03/19 13:05
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.